SVB Leerink Downgrades Pacira Pharmaceuticals (PCRX) to Market Perform
Tweet
Share
E-mailGet Alerts PCRX Hot Sheet
Price: $26.05 -2.83%
Rating Summary:
16 Buy, 11 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
16 Buy, 11 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
SVB Leerink analyst Ami Fadia downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Outperform to Market Perform with a price target of $75.00.
For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.
Shares of Pacira Pharmaceuticals closed at $73.34 yesterday.
You May Also Be Interested In
- Citi Upgrades Sirius XM Radio (SIRI) to Neutral, 'risk-reward is balanced at prevailing levels'
- Jefferies Downgrades Hang Zhou Great Star Industrial Co (002444:CH) to Hold
- Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
